Cultural advice

The Australian National University acknowledges, celebrates and pays our respects to the Ngunnawal and Ngambri people of the Canberra region and to all First Nations Australians on whose traditional lands we meet and work, and whose cultures are among the oldest continuing cultures in human history.

Aboriginal and Torres Strait Islander peoples are advised that ANU Library collections may include images, names, voices, and other representations of deceased persons.

Material in the collection may contain terms, language or views that reflect the period in which the item was created and may be considered inappropriate today.

Genetic heterologous prime-boost vaccination strategies for improved systemic and mucosal immunity

Simple item page
dc.contributor.authorRamshaw, Ianen_AU
dc.contributor.authorRanasinghe, Charanien_AU
dc.date.accessioned2015-12-08T22:46:04Z
dc.date.issued2009
dc.date.updated2016-02-24T10:26:54Z
dc.description.abstractIn this article, we discuss the advantages and progress made with heterologous prime-boost vaccination strategies. Although the consecutive use of DNA and recombinant viral vectors induce greatly enhanced and sustained levels of both cell-mediated and humoral immunity in preclinical models, the results have not yet been translated to clinical use. Despite this, there is still a high level of optimism that these strategies offer the best hope for the development of vaccines against diseases for which there are no effective vaccines currently available. In this article, we discuss how prime-boost immunization can elicit improved mucosal immunity, how 'mucosal' regimes also elicit 'high-quality' (high-avidity) T-cell responses to vaccine antigens, and the use of cytokines/chemokines as genetic adjuvants.
dc.identifier.issn1476-0584
dc.identifier.urihttp://hdl.handle.net/1885/37986
dc.publisherFuture Drugs Ltd
dc.sourceExpert Review of Vaccines
dc.subjectKeywords: chemokine; cytokine; Human immunodeficiency virus vaccine; virus vector; CD8+ T lymphocyte; cellular immunity; correlation analysis; cytotoxic T lymphocyte; genetic analysis; human; Human immunodeficiency virus infection; humoral immunity; immune response Cell-mediated immunity; Costimulatory molecule; DNA vaccine; HIV; Mucosal vaccine; Prime-boost; T-cell avidity
dc.titleGenetic heterologous prime-boost vaccination strategies for improved systemic and mucosal immunity
dc.typeJournal article
local.bibliographicCitation.issue9
local.bibliographicCitation.lastpage1181
local.bibliographicCitation.startpage1171
local.contributor.affiliationRanasinghe, Charani, College of Medicine, Biology and Environment, ANU
local.contributor.affiliationRamshaw, Ian, College of Medicine, Biology and Environment, ANU
local.contributor.authoruidRanasinghe, Charani, u4107621
local.contributor.authoruidRamshaw, Ian, u8202754
local.description.embargo2037-12-31
local.description.notesImported from ARIES
local.identifier.absfor110799 - Immunology not elsewhere classified
local.identifier.ariespublicationu4020362xPUB156
local.identifier.citationvolume8
local.identifier.doi10.1586/erv.09.86
local.identifier.scopusID2-s2.0-70249114127
local.identifier.thomsonID000270119100009
local.type.statusPublished Versionen_AU

Downloads

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
01_Ranasinghe_Genetic_heterologous_2009.pdf
Size:
302.52 KB
Format:
Adobe Portable Document Format
Download

Collections

ANU Research Publications

DSpace software copyright © 2002-2026 LYRASIS